Howard Group has leased 7,644 sq ft at The Works at Unity Campus, Cambridge, to biotech company Maxion Therapeutics.
The company has taken Suite 4, which is fully fitted to CL2 laboratory standards and consists of two cell culture labs, an equipment room and two general purpose labs, as well as a wash-up and store area. The suite also offers office and write-up space, plus ancillary meeting rooms and a kitchenette.
Maxion is taking the space from Summit Therapeutics, which surrendered its lease on the suite to relocate its R&D activities to the US.
John McCafferty, CEO of Maxion Therapeutics, said: “Following our successful series A fundraise earlier this year our team has rapidly grown, with the corresponding need for expanded facilities in the Cambridge area. We are excited to move to Unity Campus as we accelerate the development of our innovative pipeline of candidate therapeutics – with the ultimate goal of improving the quality of life of patients with debilitating disease conditions.”
Katherine Friend, director of investment and asset management at the Howard Group, added: “We are thrilled that Maxion Therapeutics has joined the Unity Campus community, and particularly pleased to welcome John McCafferty and Aneesh Karatt Vellatt back with their latest venture. Maxion joins an exciting and innovative campus community which, in addition to undertaking ground-breaking research, also values the opportunity to interact and collaborate with each other outside the lab within the campus ecosystem.
“The campus team provide a regular series of networking, professional development and social events to facilitate these interactions and we look forward to getting to know the Maxion Therapeutics team as they settle in over the next few weeks.”
Savills and JLL are joint agents at Unity Campus.
